KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Results of a Randomized Augmented Intensification Phase in Acute Lymphoblastic Leukemia in Children in Argentina: GATLA 2010 ALL IC Trial.

Maria C Riccheri, Sergio M Gomez, Alejandra Deana, Alcira B Fynn, Pedro Negri-Aranguren, Guillermo Arbesu, Graciela Elena, Horacio Caferri, Alejandra Cedola, Marcela Soria, Paola Reichel, Monika Makiya, Carlos Hollmann, Sandra Borchichi, Cristina Ferraro, Virginia Schuttenberg, Mercedes Tomassetti, Mae Arrieta, Eduardo Dibar, Lillian Sung

Pediatr Blood Cancer 72(10) e31886

PMID40635183
PMCID-
DOI10.1002/pbc.31886
发表日期2025-07-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Intensified postinduction therapy improves outcomes for high-risk pediatric patients with acute lymphoblastic leukemia (ALL) in high-income countries. However, benefits are uncertain in middle-income countries where supportive care is often limited. The primary objective was to determine if augmented protocal I phase B (IB) reduced the 5-year cumulative incidence of relapse compared with standard IB among newly diagnosed pediatric patients with intermediate- and high-risk (IR and HR) ALL in a middle-income country. METHODS: This was a randomized, phase III multicenter study conducted in 30 centers from GATLA group in Argentina, as part of International BFM study group ALLIC. We included newly diagnosed pediatric patients with ALL 1-18 years of age with IR or HR B- and T-precursor ALL. Only patients who were in complete remission at end induction were randomized to augmented IB versus standard IB. Augmented IB consisted of cyclophosphamide, cytarabine, 6-mercaptopurine, vincristine, E. coli l-asparaginase and intrathecal methotrexate. Standard IB consisted of cyclophosphamide, 6-mercaptopurine, cytarabine, and intrathecal methotrexate. The primary outcome was the cumulative incidence of relapse. RESULTS: There were 1060 patients randomized to standard IB (n = 527) and augmented IB (n = 533). The 5-year cumulative incidence of relapse (±standard error) was not significantly different by group (22.6 ± 0.2 vs. 22.3 ± 0.1%; p = 0.97) for standard IB and augmented IB, respectively. Treatment-related mortality (TRM) was 6.5 ± 0.1 and 7.5 ± 0.1%; p = 0.45, respectively. CONCLUSIONS: Among newly diagnosed pediatric patients with IR and HR ALL treated in Argentina, postinduction intensification with augmented IB did not improve outcomes compared with standard IB. Standard IB should be used for these patients. Future trials should focus on reducing TRM.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。